Display options
Cite
Murasaki M, Koyama T, Kanba S, et al. Correction to: Multi-center, randomized, double-blind, placebocontrolled study of quetiapine extended-release formulation in Japanese patients with bipolar depression. Psychopharmacology (Berl). 2018;235(10):3079-3080doi: 10.1007/s00213-018-5013-6.
Murasaki, M., Koyama, T., Kanba, S., Takeuchi, M., Shimizu, Y., Arita, E., Kuroishi, K., Takeuchi, M., & Kamei, S. (2018). Correction to: Multi-center, randomized, double-blind, placebocontrolled study of quetiapine extended-release formulation in Japanese patients with bipolar depression. Psychopharmacology, 235(10), 3079-3080. https://doi.org/10.1007/s00213-018-5013-6
Murasaki, Mitsukuni, et al. "Correction to: Multi-center, randomized, double-blind, placebocontrolled study of quetiapine extended-release formulation in Japanese patients with bipolar depression." Psychopharmacology vol. 235,10 (2018): 3079-3080. doi: https://doi.org/10.1007/s00213-018-5013-6
Murasaki M, Koyama T, Kanba S, Takeuchi M, Shimizu Y, Arita E, Kuroishi K, Takeuchi M, Kamei S. Correction to: Multi-center, randomized, double-blind, placebocontrolled study of quetiapine extended-release formulation in Japanese patients with bipolar depression. Psychopharmacology (Berl). 2018 Oct;235(10):3079-3080. doi: 10.1007/s00213-018-5013-6. PMID: 30221314; PMCID: PMC6828439.
Copy Download .nbib Format: NLM
Share it on

Psychopharmacology (Berl). 2018 Oct;235(10):3079-3080. doi: 10.1007/s00213-018-5013-6.

Correction to: Multi-center, randomized, double-blind, placebocontrolled study of quetiapine extended-release formulation in Japanese patients with bipolar depression.

Psychopharmacology

Mitsukuni Murasaki, Tsukasa Koyama, Shigenobu Kanba, Masahiro Takeuchi, Yuriko Shimizu, Eri Arita, Kentaro Kuroishi, Masahiro Takeuchi, Shinya Kamei

Affiliations

  1. Institute of CNS Pharmacology, 3-14-20 Sagamiohno, Minami-ku, Sagamihara, Kanagawa, 252-0303, Japan.
  2. Ohyachi Hospital, Clinical Research Center, 5-7-10 Ohyachi-higashi, Atsubetsu-ku, Sapporo, Hokkaido, 004-0041, Japan.
  3. Department of Neuropsychiatry, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.
  4. Department of Clinical Medicine, School of Pharmacy, Kitasato University, 5-9-1 Shirokane, Minato-ku, Tokyo, 108-8641, Japan.
  5. Japan/Asia Clinical Development 2, Astellas Pharma Inc., 2-5-1 Nihonbashi-Honcho, Chuo-ku, Tokyo, 103-8411, Japan.
  6. Global Clinical Science, Astellas Pharma Europe B.V, Sylviusweg 62, PO Box 344, 2300 AH, Leiden, The Netherlands.
  7. Japan-Asia Data Science, Astellas Pharma Inc., 2-5-1 Nihonbashi-Honcho, Chuo-ku, Tokyo, 103-8411, Japan.
  8. Astellas Pharma Global Development, Inc., 1 Astellas Way, Northbrook, IL, 60062, USA.
  9. Japan/Asia Clinical Development 2, Astellas Pharma Inc., 2-5-1 Nihonbashi-Honcho, Chuo-ku, Tokyo, 103-8411, Japan. [email protected].

PMID: 30221314 PMCID: PMC6828439 DOI: 10.1007/s00213-018-5013-6

Abstract

The original version of this article contained a mistake in Table 5. Correct version is presented here.

Publication Types